Reported Reactions

Drugs

Product name as reported

Carbon Monoxide: adverse event reports filed with FDA

607 reports list it as a suspect or interacting product, 2004–2026.

607
reports as suspect product
0% of all reports · about 27 a year
5
reports, 12 months to June 2026
15 in the 12 months before
99.7%
marked serious by the reporter
57.4% across all reports
93.2%
record death among outcomes, as reported
566 reports · not verified by FDA

607 adverse event reports received by FDA list the product name "Carbon Monoxide" as reporters wrote it as a suspect or interacting product, from June 2004 to April 2026. A further 13 reports list it only as a concomitant medication, and those are not counted in the figures on this page.

In the 12 months to June 2026, 5 reports listed it, down 67% from 15 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 27 reports a year and 0% of the 20,646,523 reports in the database. How many people take it is not in the data, so a count is not a rate of occurrence.

Reporters most often recorded completed suicide (45.8%), toxicity to various agents (24.4%) and death (14.3%). A report can list several reactions, so shares add to more than 100%; 140 different terms appear across these reports. Completed suicide is recorded in 45.8% of these reports, against 0.4% of all reports in the database.

99.7% of the reports are marked serious by the reporter; 93.2% record death among the outcomes and 14.3% record hospitalisation, as reported. 46.3% of the reports came from physicians, and the largest patient age group is 45 to 64 (41.5%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

0510Jul 2021: 3Aug 2021: 0Sep 2021: 0Oct 2021: 0Nov 2021: 0Dec 2021: 12022Jan 2022: 4Feb 2022: 9Mar 2022: 3Apr 2022: 0May 2022: 0Jun 2022: 0Jul 2022: 0Aug 2022: 0Sep 2022: 1Oct 2022: 1Nov 2022: 0Dec 2022: 02023Jan 2023: 10Feb 2023: 1Mar 2023: 0Apr 2023: 8May 2023: 0Jun 2023: 0Jul 2023: 0Aug 2023: 0Sep 2023: 0Oct 2023: 0Nov 2023: 0Dec 2023: 12024Jan 2024: 8Feb 2024: 6Mar 2024: 0Apr 2024: 3May 2024: 0Jun 2024: 0Jul 2024: 0Aug 2024: 0Sep 2024: 0Oct 2024: 0Nov 2024: 0Dec 2024: 22025Jan 2025: 9Feb 2025: 1Mar 2025: 1Apr 2025: 1May 2025: 1Jun 2025: 0Jul 2025: 1Aug 2025: 1Sep 2025: 0Oct 2025: 0Nov 2025: 0Dec 2025: 02026Jan 2026: 1Feb 2026: 1Mar 2026: 0Apr 2026: 1May 2026: 0Jun 2026: 0

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

0631262004: 520042005: 162006: 102007: 620072008: 122009: 162010: 620102011: 202012: 102013: 3920132014: 582015: 1262016: 1220162017: 492018: 322019: 4920192020: 432021: 232022: 1820222023: 202024: 192025: 1520252026: 3

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Carbon Monoxide reports recording the termall reports in the database

  1. Completed suicidedeath by suicide45.8%278
  2. Toxicity to various agentspoisoning or toxic effect of one or more substances24.4%148
  3. Deaththe patient died; cause not stated by this term14.3%87
  4. Environmental exposure12.5%76
  5. Cardio-respiratory arrestthe heart and breathing stopped12%73
  6. Cardiac arrestthe heart stopped10.7%65
  7. Respiratory arrestbreathing stopped10.2%62
  8. Carbon monoxide poisoning4%24
  9. Intentional overdosea deliberate overdose3.1%19
  10. Poisoning2.8%17
  11. Incorrect route of product administrationthe product was given by the wrong route1.8%11
  12. Overdosea dose above the recommended amount1.8%11
  13. Suspected suicide1.6%10
  14. Exposure via inhalation1.5%9
  15. Suicide attempta suicide attempt1.5%9
  16. Exposure via ingestion1.3%8
  17. Drug abusemisuse of a medicine1.2%7
  18. Incorrect route of drug administrationthe medicine was given by the wrong route1%6
  19. Lactic acidosisa build-up of lactic acid in the blood1%6
  20. Multiple drug overdose1%6
  21. Pulmonary oedemafluid in the lungs1%6
  22. Exposure to toxic agent0.8%5
  23. Intentional product misusedeliberate use not as intended0.8%5
  24. Amnesiamemory loss0.7%4
  25. Blood carbon monoxide increased0.7%4
  26. Hypersensitivityan allergic-type reaction0.7%4
  27. Multiple drug overdose intentional0.7%4

Top 30 of 140 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Death93.2%566
Life-threatening1.5%9
Hospitalisation (initial or prolonged)14.3%87
Disability0%0
Congenital anomaly0%0
Other serious24.4%148
Not serious0.3%2

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Patient age

Under 20%0
2 to 110.3%2
12 to 171%6
18 to 4431.6%192
45 to 6441.5%252
65 to 749.9%60
75 and over10.2%62
Age not given5.4%33

Patient sex

Female36.1%219
Male57.2%347
Not given6.8%41

Who reported

Physician46.3%281
Pharmacist22.1%134
Other health professional24.5%149
Lawyer0.7%4
Consumer or non-health professional2.6%16
Not given3.8%23

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 93.7% of reports give the United States as the country of the event or reporter.

Reason for use recorded

Indication as recorded (MedDRA)ReportsShare
Suicide attempt254.1%
Completed suicide40.7%
Poisoning deliberate20.3%

The indication field is filled in by the reporter and is often blank; shares are of all 607 reports.

In context

MeasureCarbon MonoxideAll reports
Reports as suspect product60720,646,523
Share of that pool—0%
Reports, latest 12 months51,332,454
Marked serious99.7%57.4%
Death recorded among outcomes, per 1,000 reports93291
Hospitalisation recorded, per 1,000 reports143213
Consumer-filed share2.6%45.8%
Top term, share of reportsCompleted suicide 45.8%0.4%

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Questions about Carbon Monoxide reports

How many adverse event reports has FDA received for Carbon Monoxide?

607 reports list Carbon Monoxide as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 5 of them arrived in the latest 12 months. Another 13 list it only as a concomitant medication.

What reactions are recorded in Carbon Monoxide reports?

completed suicide (45.8%), toxicity to various agents (24.4%), death (14.3%), environmental exposure (12.5%) and cardio-respiratory arrest (12%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Carbon Monoxide was responsible.

How serious are the reports?

99.7% are marked serious by the reporter. Among the outcomes recorded, 93.2% of reports include death and 14.3% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.

Who files these reports?

physician (46.3%), other health professional (24.5%) and pharmacist (22.1%). Most reports reach FDA through the manufacturer, which must forward reports it receives.

Are reports for Carbon Monoxide rising?

5 reports in the 12 months to June 2026, down 67% from 15 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.

Do these reports show that Carbon Monoxide was responsible for these reactions?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.

Is this a list of the side effects of Carbon Monoxide?

No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.

How do I report an adverse event?

Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Carbon Monoxide as a suspect or interacting product; reports listing it only as a concomitant medication (13) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.